FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2265067466> ?p ?o ?g. }

• W2265067466 endingPage "e215" @default.
• W2265067466 startingPage "e214" @default.
• W2265067466 abstract "Insulinomas are the most common islet cell tumors, arising from the β-cells of the pancreas. They are the most frequent hormone-active tumor of the pancreas and are the most common cause of hypoglycemia in patients who do not have a systemic illness. They are rare, however, with an incidence of 0.4 per 100,000 persons per year. Characterizing insulinomas as neuroendocrine in nature and localizing them to allow for surgical resection is crucial to the diagnosis and treatment of these tumors. In this issue of AACE Clinical Case Reports, Kyrilli et al (1.Kyrilli A. Igoillo-Esteve M. Féry F. et al.Insulinoma localization by glucagon-like peptide-1 receptor imaging after 18 years of hypoglycemia.ACCE Clinical Case Rep. 2015; 1: e187-e193Scopus (1) Google Scholar) describe the successful localization of a small insulinoma that remained undetected for the previous 18 years. Failed attempts were made to localize the tumor, including surgical exploration with resection of a benign nodule, intraarterial calcium injection with venous sampling, and imaging with the more traditional imaging modalities of dualphase computed tomography, ultrasound (US), and pancreatic magnetic resonance imaging (MRI). The authors also employed the somatostatin receptor binding radiotracer 111Indium octreotide. This radiotracer is commonly used in clinical practice, despite a relatively low sensitivity for insulinomas, estimated to be 50% for planar imaging and 80% for single-photon emission computed tomography (SPECT), with rare detection of lesions <2 cm in size. Failed attempts were also made with the radiotracers 68Gallium-DOTATATE-positron emission tomography (PET), a less commonly used somatostatin receptor binding agent, with 18F-fluoro-DOPA-PET that reflects increased L-DOPA decarboxylase activity, and with 11C-methionine PET that reflects increased amino acid utilization. This case report describes success with localizing a small insulinoma using SPECT/CT employing the groundbreaking β-cell-specific novel radiopeptide [Lys40 AHx-diethylene triamine-pentaacetate (DTPA)-111IndiumNH2]-exendin-4, which is a highly stable glucagon-like peptide-1 (GLP-1) receptor ligand radiolabeled with the radioisotope 111Indium. This localization is based on the high density of GLP-1 receptors, which are overexpressed in almost all insulinoma cells, both benign and malignant. Using the area of high 111Indium-DTPA-exendin-4 uptake on the SPECT/CT in the pancreatic tail as a roadmap, endoscopic US confirmed the presence of a small 15 × 9 mm pancreatic tail nodule. Coregistration of the SPECT/CT hybrid scanner images with the MRI undoubtedly facilitated the identification of the lesion by the radiologist retrospectively on MRI. Surgical excision resulted in cure, and the authors describe the histology and extensive ex vivo functional characterization of the insulinoma, including abundant GLP-1 receptor expression. The authors provide explanations for the success of this 111Indium-DTPA-exendin-4 radiotracer in localizing the insulinoma, and they use the findings from their careful tumor tissue analysis to offer explanations as to why the other radiotracers and selective arterial calcium stimulation failed to localize the lesion. This case adds evidence to the existing literature that some insulinomas are very difficult to localize using traditional methods and imaging modalities and that novel radioisotopes that do not rely on somatostatin receptors are needed. When insulinomas present clinically, they are usually small and intrapancreatic, with surgery being curative. Noninvasive localization is critical for planning surgery, as blind distal pancreatectomy may not be curative and can lead to complications. Insulinomas are also multiple in 13% of cases (2.Wicki A. Wild D. Storch D. et al.[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.Clin Cancer Res. 2007; 13: 3696-3705Crossref PubMed Scopus (84) Google Scholar). Accurate localization allowing for surgical removal results in 88% survival at 10 years. Unfortunately, 10% of insulinomas become malignant and can metastasize to other sites, resulting in a median survival of 2 years and 10-year survival of 29% (2.Wicki A. Wild D. Storch D. et al.[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.Clin Cancer Res. 2007; 13: 3696-3705Crossref PubMed Scopus (84) Google Scholar). This paper reinforces the work published by Christ et al (3.Christ E. Wild D. Ederer S. et al.Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.Lancet Diabetes Endocrinol. 2013; 1: 115-122Abstract Full Text Full Text PDF PubMed Scopus (120) Google Scholar) in 2013, which demonstrated that 111Indium-DTPA-exendin-4 has a positive predictive value of 83%, with 95% sensitivity, compared to a sensitivity of 47% with CT/MRI. Kyrilli et al conclude that GLP receptor imaging “should be used to localize insulinomas whenever conventional methods fail.” This tracer holds promise because it appears to be able to detect lesions as small as 7 mm in size using a combined SPECT/CT with fused images (the CT provides correction for the attenuation of photons by the body and provides the anatomic correlation). The case and the discussion provided will encourage the availability of this 111Indium-DTPA-exendin-4 GLP-1 receptor agonist radiotracer to aid in the localization of insulinomas when needed. The future impact of the use of this particular radiopeptide also includes the potential to measure β-cell mass to monitor the dynamics of β-cell loss and regeneration in diabetics, as seen in animal models using 111Indium-exendin-3 radiotracer (4.Tiedge M. Inside the pancreas: progress and challenges of human beta cell mass quantification.Diabetologia. 2014; 57: 856-859Crossref Scopus (12) Google Scholar). In addition, there are animal studies looking at the potential of using the 111Indium-DTPA-exendin-4 GLP-1 receptor agonist as a therapeutic agent to deliver targeted radiotherapy to insulinomas (2.Wicki A. Wild D. Storch D. et al.[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.Clin Cancer Res. 2007; 13: 3696-3705Crossref PubMed Scopus (84) Google Scholar)." @default.
• W2265067466 created "2016-06-24" @default.
• W2265067466 creator A5029911867 @default.
• W2265067466 date "2015-01-01" @default.
• W2265067466 modified "2023-09-26" @default.
• W2265067466 title "Detection of a Small Insulinoma Using a Novel Glucagon-Like Peptide-1 Receptor Ligand" @default.
• W2265067466 cites W1981756512 @default.
• W2265067466 cites W2023763957 @default.
• W2265067466 cites W2078004461 @default.
• W2265067466 cites W2102393399 @default.
• W2265067466 doi "https://doi.org/10.4158/ep14599.co" @default.
• W2265067466 hasPublicationYear "2015" @default.
• W2265067466 type Work @default.
• W2265067466 sameAs 2265067466 @default.
• W2265067466 citedByCount "0" @default.
• W2265067466 crossrefType "journal-article" @default.
• W2265067466 hasAuthorship W2265067466A5029911867 @default.
• W2265067466 hasBestOaLocation W22650674661 @default.
• W2265067466 hasConcept C126322002 @default.
• W2265067466 hasConcept C126838900 @default.
• W2265067466 hasConcept C143409427 @default.
• W2265067466 hasConcept C2775842073 @default.
• W2265067466 hasConcept C2775858560 @default.
• W2265067466 hasConcept C2776297358 @default.
• W2265067466 hasConcept C2778563252 @default.
• W2265067466 hasConcept C2778764654 @default.
• W2265067466 hasConcept C2779066768 @default.
• W2265067466 hasConcept C2779306644 @default.
• W2265067466 hasConcept C2780053029 @default.
• W2265067466 hasConcept C2780668416 @default.
• W2265067466 hasConcept C2989005 @default.
• W2265067466 hasConcept C71315377 @default.
• W2265067466 hasConcept C71924100 @default.
• W2265067466 hasConcept C80115893 @default.
• W2265067466 hasConceptScore W2265067466C126322002 @default.
• W2265067466 hasConceptScore W2265067466C126838900 @default.
• W2265067466 hasConceptScore W2265067466C143409427 @default.
• W2265067466 hasConceptScore W2265067466C2775842073 @default.
• W2265067466 hasConceptScore W2265067466C2775858560 @default.
• W2265067466 hasConceptScore W2265067466C2776297358 @default.
• W2265067466 hasConceptScore W2265067466C2778563252 @default.
• W2265067466 hasConceptScore W2265067466C2778764654 @default.
• W2265067466 hasConceptScore W2265067466C2779066768 @default.
• W2265067466 hasConceptScore W2265067466C2779306644 @default.
• W2265067466 hasConceptScore W2265067466C2780053029 @default.
• W2265067466 hasConceptScore W2265067466C2780668416 @default.
• W2265067466 hasConceptScore W2265067466C2989005 @default.
• W2265067466 hasConceptScore W2265067466C71315377 @default.
• W2265067466 hasConceptScore W2265067466C71924100 @default.
• W2265067466 hasConceptScore W2265067466C80115893 @default.
• W2265067466 hasIssue "3" @default.
• W2265067466 hasLocation W22650674661 @default.
• W2265067466 hasOpenAccess W2265067466 @default.
• W2265067466 hasPrimaryLocation W22650674661 @default.
• W2265067466 hasRelatedWork W1972658116 @default.
• W2265067466 hasRelatedWork W2001608868 @default.
• W2265067466 hasRelatedWork W2064757739 @default.
• W2265067466 hasRelatedWork W2120766385 @default.
• W2265067466 hasRelatedWork W2208993529 @default.
• W2265067466 hasRelatedWork W2294029518 @default.
• W2265067466 hasRelatedWork W2373744563 @default.
• W2265067466 hasRelatedWork W2395258867 @default.
• W2265067466 hasRelatedWork W4285491473 @default.
• W2265067466 hasRelatedWork W2550150756 @default.
• W2265067466 hasVolume "1" @default.
• W2265067466 isParatext "false" @default.
• W2265067466 isRetracted "false" @default.
• W2265067466 magId "2265067466" @default.
• W2265067466 workType "article" @default.